Mechanism of Action KEYTRUDA® (pembrolizumab): PD-1 Receptor Blockade KEYTRUDA binds to the PD-1 receptor, blocking both immune-suppressing ligands, PD‑L1 and PD‑L2, from interacting with PD-1 to help restore T-cell response and immune response...
Based on the results of one phase III multicenter trial, Keytruda is superior to chemotherapy in the first-line treatment of MSI-H or dMMR CRC, resulting in longer PFS and fewer treatment-related adverse events.384 Other potential therapies Current chemotherapy for CRLM is still not desirable ...
In 1889, Paget proposed the concepts of “seed” (tumor cells) and “soil” (specific organs) for tumor metastasis.28The liver metastatic cascade of CRC is a complex multi-factor and multi-step biological process (Fig.1), wherein a small subset of CRC cells acquire a capacity to evade f...